

CITATION REPORT

List of articles citing

Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial

DOI: 10.1001/jama.287.6.719

JAMA - Journal of the American Medical Association, 2002, 287, 719-25.

Source: <https://exaly.com/paper-pdf/33965870/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
141	Cardiovascular safety in erectile dysfunction treatment. 2002 , 2, 301-304		5
140	Neurogenic Bladder, Neurogenic Bowel, and Sexual Dysfunction in People With Spinal Cord Injury. 2002 , 82, 601-612		170
139	The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. 2002 , 40, 2006-12		120
138	Management of Erectile Dysfunction. 2002 , 10, 431-452		5
137	MMR vaccine: no evidence for new variant of autism. 2002 , &NA;, 20		
136	Efavirenz: associated with HIV dementia and depression. 2002 , &NA;, 4		
135	Introduction. The management of erectile dysfunction (ED). 2002 , 60, 1-3		4
134	A 4-year update on the safety of sildenafil citrate (Viagra). 2002 , 60, 67-90		188
133	[Cardio-vascular effects of sildenafil: new data]. 2002 , 51, 341-5		3
132	Erectile dysfunction in the cardiac patient. 2003 , 4, 466-71		16
131	Sildenafil in patients with cardiovascular disease. 2003 , 92, 26M-36M		32
130	Comparison of supine bicycle exercise and treadmill exercise Doppler echocardiography in evaluation of patients with coronary artery disease. 2003 , 91, 1245-8		20
129	Modern management of acute myocardial infarction. 2003 , 28, 7-127		
128	Hemi-retinal artery occlusion associated with sexual activity and sildenafil citrate (Viagra). 2003 , 81, 198-200		13
127	Pharmacological management of erectile dysfunction. 2003 , 91, 446-54		74
126	Sildenafil and coronary artery disease. 2003 , 92, 824-5		3
125	Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study. 2003 , 169, 1048-51		35

124	Effects of sildenafil on cardiopulmonary responses during stress. 2003 , 169, 1417-21	6
123	Use of medications for erectile dysfunction in the United States, 1996 through 2001. 2003 , 169, 1040-2	23
122	Disorders of male sexual function. 2003 , 19, 473-81, v	15
121	Nitric oxide-releasing drugs. 2003 , 43, 97-123	178
120	Erectile dysfunction. 2003 , 54, 153-68	66
119	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. <i>Circulation</i> , 2003 , 108, 239-44	16.7 124
118	Sildenafil in erectile dysfunction: a critical review. 2003 , 19, 241-62	77
117	Sildenafil citrate does not affect cardiac contractility in human or dog heart. 2003 , 19, 747-52	59
116	Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. 2003 , 64, 533-46	260
115	Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. 2004 , 93, 796-801	36
114	Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. 2004 , 24, 63-8	30
113	Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis. 2004 , 9, 228-33	5
112	Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5). 2004 , 16, 412-7	12
111	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. 2004 , 93, 147-53	80
110	Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient. 2004 , 23, 125-9	14
109	Role of the cardiologist: Clinical aspects of managing erectile dysfunction. 2004 , 27, 3-7	7
108	Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. 2004 , 27, 120-5	22
107	Quelles investigations, le non-spécialiste doit-il demander devant un patient consultant pour un dysfonctionnement érectile?. 2004 , 14, 291-306	0

106	Erectile dysfunction in the cardiac patient. 2004 , 30, 50-4	6
105	Efficiency of the cross-over design: an empirical estimation. 2004 , 23, 3773-80	29
104	Erectile dysfunction and cardiovascular disease. 2004 , 79, 782-94	14
103	Coronary artery risk factors in patients with erectile dysfunction. 2004 , 172, 251-4	82
102	Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. <i>Circulation</i> , 2004 , 110, 3149-55	16.7 143
101	Erectile dysfunction: evaluation and new treatment options. 2004 , 66, 664-71	29
100	Erectile Dysfunction and Cardiovascular Disease. 2004 , 79, 782-794	49
99	Effects of sildenafil citrate on hepatic function and regeneration in normal and alcohol-fed rats. 2005 , 25, 913-9	8
98	Phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 96, 257-80	153
97	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). 2005 , 59, 680-91	61
96	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. 2005 , 60, 459-68	19
95	Erectile dysfunction in patients with coronary artery disease. 2005 , 17, 209-15	19
94	A case of erectile dysfunction and risk factors for coronary artery disease. 2005 , 17 Suppl 1, S7-S11	3
93	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. 2005 , 95, 36-42	51
92	Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease. 2005 , 95, 327-31	13
91	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). 2005 , 96, 313-21	216
90	Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. 2005 , 96, 32M-36M	17
89	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). 2005 , 96, 85M-93M	99

88	The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs. 2005 , 28 Suppl 2, 69-73		2
87	Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. <i>Journal of Sexual Medicine</i> , 2005 , 2, 40-50; discussion 50-2	1.1	112
86	Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2005 , 2, 407-14	1.1	15
85	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. 2005 , 23, 374-84		25
84	[Therapy for organic erectile dysfunction]. <i>Der Urologe</i> , 2005 , 44, 1160-6		2
83	Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. <i>Circulation</i> , 2005 , 112, 2642-7	1.1	142
82	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 2, 239-47		40
81	Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy. 2005 , 51, 15-31		23
80	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72		4
79	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72		0
78	Acute myocardial infarction after sildenafil citrate ingestion. 2005 , 39, 1362-4		8
77	Erectile dysfunction: the need to be evaluated, the right to be treated. 2005 , 150, 620-6		14
76	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. 2005 , 4, 531-40		18
75	PDE-5 inhibitors: current status and future trends. 2005 , 32, 511-25, viii		25
74	Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. 2005 , 22, 823-44		17
73	Safety and tolerability of oral erectile dysfunction treatments in the elderly. 2005 , 22, 323-38		5
72	Effects of sildenafil citrate (Viagra) on renal arteries: an evaluation with Doppler ultrasound. 2006 , 77, 170-2		4
71	Evaluation and medical management of erectile dysfunction. 2006 , 81, 385-90		17

70	An overview of the diagnosis and treatment of erectile dysfunction. 2006 , 66, 2339-55	17
69	Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. 2006 , 68, 47-60	55
68	Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. 2006 , 17, 493-9	8
67	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702	366
66	Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness. 2006 , 18, 423-31	26
65	Sudden cardiovascular death associated with sexual activity : A forensic autopsy study (1972-2004). 2006 , 2, 109-14	26
64	[Erectile dysfunction, a new symptom for the cardiologist]. 2006 , 55, 187-91	2
63	Sex, the heart, and heart failure. 2006 , 10, 256-8	5
62	Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment. 2006 , 4, 173-80	14
61	Chronic sildenafil in men with diabetes and erectile dysfunction. 2007 , 3, 451-64	24
60	Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. 2007 , 334, 466-80	14
59	Are nitrates safe in patients who use sildenafil? Maybe. 2007 , 35, 1988-90	5
58	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. 2007 , 15, 76-86	52
57	Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. 2007 , 35, 1863-8	18
56	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. 2007 , 19, 281-95	33
55	Helping the failing heart and penis. 2007 , 61, 716-8	
54	Right ventricular function with hypoxic exercise: effects of sildenafil. 2007 , 102, 87-95	22
53	Failure is an option: learning from unsuccessful proof-of-concept trials. 2008 , 13, 913-6	26

52	Does sildenafil cause myocardial infarction or sudden cardiac death?. 2008 , 8, 1-7		18
51	The right ventricle in sepsis. 2008 , 29, 661-76, ix		53
50	The cardiovascular safety of tadalafil. 2008 , 7, 43-52		8
49	Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1alpha signaling. 2008 , 233, 1222-30		36
48	Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. 2008 , 133, 744-55		81
47	Cardiovascular effects of noncardiovascular drugs. <i>Circulation</i> , 2009 , 120, 1123-32	16.7	17
46	Cardiovascular effects of phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , 2009 , 6, 658-74.1	4.1	38
45	[Erectile dysfunction in the cardiovascular patient]. 2009 , 132, 309-10		
44	Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. 2009 , 3, 201-211		1
43	[Erectile dysfunction and renal chronic insufficiency: etiology and management]. 2009 , 19, 1-7		4
42	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2010 , 7, 524-40	1.1	132
41	Sildenafil prevents mortality and reduces hippocampal damage after permanent, stepwise, 4-vessel occlusion in rats. <i>Brain Research Bulletin</i> , 2010 , 81, 631-40	3.9	11
40	Traitement de la dysfonction érectile. <i>EMC - Traitement de Médecine AKOS</i> , 2011 , 6, 1-7		
39	Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview. <i>Cardiovascular Toxicology</i> , 2011 , 11, 285-307	3.4	23
38	Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i> , 2012 , 125, 1058-72	16.7	202
37	10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. <i>Journal of Sexual Medicine</i> , 2012 , 9, 265-70	1.1	31
36	Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 53-64	2.6	17
35	A systematic review of the association between erectile dysfunction and cardiovascular disease. <i>European Urology</i> , 2014 , 65, 968-78	10.2	267

34	Sexual activity and ischemic heart disease. <i>Current Cardiology Reports</i> , 2014 , 16, 445	4.2	15
33	Acute effect of sildenafil on myocardial ischemic territories in patients with stable coronary artery disease. <i>Egyptian Heart Journal</i> , 2014 , 66, 43-48	1.3	0
32	Cardiovascular Toxicity of Noncardiovascular Drugs. 2015 , 305-339		0
31	Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2281-2289	4	1
30	[Side effects of erectile dysfunction drug treatment]. <i>Der Urologe</i> , 2017 , 56, 451-455		2
29	Erectile Dysfunction and Ischaemic Heart Disease. <i>European Cardiology Review</i> , 2018 , 13, 98-103	3.9	16
28	Sildenafil enhances central hemodynamic responses to exercise, but not V o, in people with diabetes mellitus. <i>Journal of Applied Physiology</i> , 2019 , 127, 1-10	3.7	1
27	CONSORT 2010 statement: extension to randomised crossover trials. <i>BMJ, The</i> , 2019 , 366, l4378	5.9	118
26	Video-based assessment of drug-induced effects on contractile motion properties using human induced pluripotent stem cell-derived cardiomyocytes. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020 , 105, 106893	1.7	2
25	Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition. 2004 , 207-237		1
24	The Physiologic Cost of Sexual Activity. 2004 , 239-249		1
23	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. 2004 , 139-161		1
22	Chronic Ischaemic Heart Disease. 2009 , 597-664		5
21	Sildenafil enhances locomotor activity in young mice and exerts angiogenic effects in both young and aged mice. <i>Medical Science Monitor Basic Research</i> , 2014 , 20, 15-21	3.2	10
20	Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease. 2004 , 179-194		
19	American College of Cardiology/American Heart Association Guidelines on the Use of Sildenafil in Patients With Cardiovascular Disease. 2004 , 271-277		
18	Primary Care Issues in the Management of Erectile Dysfunction. 2004 , 229-233		
17	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181		

16

Sexual Activity As a Trigger of Myocardial Infarction/Ischemia. **2004**, 251-260

15

Cardiovascular safety of sildenafil in the treatment of erectile dysfunction. **2004**, 151-162

14

Oral Type 5 Phosphodiesterase Therapy for Male and Female Sexual Dysfunction. **2004**, 107-119

13

Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. **2004**, 129-142

12

Erectile Dysfunction Assessment and Management in Primary Care Practice. **2005**, 149-183

11

Sexual Health. **2007**, 401-407

10

Erectile Dysfunction and Cardiovascular Disease. **2007**, 2791-2801

9

Erektiler Disfonksiyon. **2010**, 384-390

8

Phosphodiesterase-5 Inhibitors in Cardioprotection. **2013**, 439-458

7

SPECIFIC PROPERTIES OF THE DRUG THERAPY FOR STABLE ANGINA IN MEN. *Cardiovascular Therapy and Prevention (Russian Federation)*, **2014**, 13, 61-640.9

6

Stress Echocardiography: A Historical Perspective. **2015**, 3-18

5

Cardiac Issues Related to Erectile Dysfunction. **2006**, 61-75

4

Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. *Reviews in Urology*, **2003**, 5 Suppl 7, S21-717

3

Erectile dysfunction in patients with cardiovascular disease. *Netherlands Heart Journal*, **2006**, 14, 139-146.2

2

Erectile dysfunction. *Clinical Evidence*, **2011**, 2011, 3

1

Stress Echocardiography. **2016**, 237-283